• Explore /
  • Poster
  • / A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.

A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.

Abstract Poster

Authors

null

James Lloyd Wade III

Heartland NCORP, Decatur, IL

James Lloyd Wade III, Corey J. Langer , Mary Redman , Charu Aggarwal , Jeffrey D Bradley , Jeffrey Crawford , Jieling Miao , Katie Griffin , Roy S. Herbst , Karen Kelly , David R. Gandara , Vassiliki Papadimitrakopoulou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02785913

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9054)

DOI

10.1200/JCO.2017.35.15_suppl.9054

Abstract #

9054

Poster Bd #

380

Abstract Disclosures

Similar Posters

First Author: Charu Aggarwal

First Author: Giorgio V. Scagliotti

First Author: Sukhmani Kaur Padda

First Author: Benedito A. Carneiro